Efficacy and safety of the extracorporeal shock wave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial

Lu Chen
Sichuan University West China Hospital

Ruihao Zhou
Sichuan University West China Hospital

Fuguo Sun
Sichuan University West China Hospital

Yan Weng
Sichuan University West China Hospital

Ling Ye (zerodq_hx@163.com)
Sichuan University West China Hospital

Pingliang Yang
The first affiliated hospital of chengdu medical college

Study protocol

Keywords: extracorporeal shockwave therapy, postherpetic neuralgia, neuropathic pain, randomized controlled trial

DOI: https://doi.org/10.21203/rs.3.rs-18731/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which seriously affects quality of life because of pain severity and poor response to the currently available treatments. The main strategies for PHN management are medication and invasive interventional therapies; however, these approaches have many adverse effects, so it is important to find another effective and safe treatment for PHN.

Methods: A single-center, single-blind randomized clinical trial will evaluate 98 study participants randomized in a 1:1 ratio into control and experimental groups. The control group will receive conventional treatment including medication therapy and invasive interventional therapy. The experimental group will receive extracorporeal shockwave therapy (ESWT) in addition to conventional therapy. The primary outcome is pain intensity assessed on a visual analogue scale (VAS); the secondary outcomes are the following: quality of life assessed by the 36-Item Short-Form Health Survey (SF-36); psychological state for anxiety and depression measured by the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS); and sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). Assessors blinded to the randomization will collect data during the intervention period at baseline and weeks 1, 4, and 12. The plasma levels of tumor necrosis factor-α and interleukin 6 will be assessed before and after ESWT to explore the biochemical mechanisms of ESWT in the treatment of PHN.

Discussion: This randomized controlled trial will evaluate the effectiveness and safety of ESWT in patients with PHN, and thus will provide clinical evidence for its use in the management of PHN and explore the potential biochemical mechanisms of this treatment.

Trial registration: www.ChiCTR.org.cn, identifier: ChiCTR1900025828. Registered on 10th September 2019

Background

Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which is defined as neuropathic pain that persists 3 months or more after the resolution of shingles (herpes zoster) (1). This neuralgia occurs in nearly 20% of patients with herpes zoster, and the risk increases with patient age, most notably between ages 50 to 79 years (2, 3). Patients with PHN may experience constant burning, itching, and sharp or lightning pain, and some may experience allodynia or hyperalgesia, which seriously affects the quality of life because of the severity of pain and the poor response to the currently available treatments (4).

The main pain management strategies for patients with PHN include medication and invasive interventional therapies. The first-line drugs include gabapentin, pregabalin, lidocaine patch 5%, and antidepressants (3). Although medication therapy is effective, a number of adverse effects (e.g., constipation, nausea and vomiting) often limit its practical use. When medication therapy cannot effectively relieve pain or if adverse effects are intolerable, then invasive interventional therapy may be considered, including nerve block, pulsed radiofrequency therapy (regulation and thermocoagulation),...
transcutaneous electrical nerve stimulation, and spinal cord stimulation (5). However, invasive interventional therapy still has risks of infection, bleeding, and nerve injury. Therefore, it is an urgent to find an effective and safe treatment for PHN.

A new technique is for managing PHN is extracorporeal shockwave therapy (ESWT), which induces single-impulse transient acoustic waves by electromagnetic, electrohydraulic, and piezoelectric devices (6). During ESWT a probe is focused on the painful area with the energy and frequency of shockwave adjusting according to the patient's reaction. Use of ESWT is increasing because it is noninvasive and has low rate of complications compared with other treatments. In addition, some studies have shown potential efficacy for ESWT in neuropathic pain such as Morton's neuroma, trigeminal neuralgia, and diabetic foot ulcers (7-11). However, no randomized controlled trial to date have confirmed the efficacy and safety of ESWT in patients with PHN or explored the potential mechanisms of action. Therefore, this randomized controlled trial will evaluate the effectiveness and safety of ESWT in patients with PHN to provide clinical evidence for its use in PHN management.

Methods

Study design

This single-center, single-blind randomized clinical trial was approved by the Ethics Committee of West China Hospital, Sichuan University, Chengdu, China (Version 2.0 of this protocol was approved on 30th December 2019, reference 2019[814]) and has been prospectively registered at Chictr.org.cn (ChiCTR1900025828) on 10th September 2019. It will be conducted in the Department of Pain Management, West China Hospital, from February 2020 to December 2020. The trial flowchart is shown in Figure 1. Additional file 1 shows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist. The schedule of enrollment, interventions, and assessments follows the SPIRIT checklist (Figure 2).

A total of 98 participants will randomized into a control group or an experimental group. Assessors blinded to the randomization will collect data during the intervention period at baseline and study weeks 1, 4, and 12. The plasma levels of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 will be detected before and after ESWT to explore the biochemical mechanisms of ESWT for the treatment of PHN.
Selection of the participants

Patients diagnosed with PHN according to the European Consensus-Based (S2k) Guideline on the Management of Herpes Zoster will be informed of this trial (12). Potential participants will be identified according to their medical record at the time of hospital admission. After a brief introduction about the trial, patients may decide whether they will participate in this study. Then detailed information will be acquired to assess patient eligibility according to following criteria (Table 1). All participants must sign the informed consent form before treatment. In the consent form, participants will be asked if they agree to use of their data after withdrawing from the trial. Participants will also be asked for the permission to share relevant data with university researchers and regulatory authorities. Participants will be informed that this trial does not involve collecting biologic specimens for the storage. Two physicians in the Department of Pain Management will approach the patients about taking part in the trial, enroll participants, and obtain their informed consent.

Table 1. Eligibility criteria
### Inclusion criteria

- Diagnosed with PHN
- VAS ≥4 points
- Age ≥18 years
- Describe symptoms clearly and have ability to self-evaluate
- Did not previously receive ESWT
- Did not participate in other clinical trials within past 3 months

### Exclusion criteria

- Allergic to medical ultrasonic couplant
- History of tumor
- Liver or kidney dysfunction
- Schizophrenia or dementia
- Cannot be followed up on schedule
- History of thrombosis
- Disturbance coagulation function using anticoagulants
- Cardiac pacemaker use
- Infection in the pain area
- Pregnant or puerperal patients
- Fracture or severe osteoporosis

**Abbreviations:** ESWT, extracorporeal shockwave therapy; PHN, postherpetic neuralgia; VAS, visual analogue scale

### Sample size

The sample size was estimated based on a previous study that used effective rates as the primary outcome (experimental group, 96%; control group, 77%) (13). Power analysis software (G*Power, version 3.1.9.4) was used with the superiority test (one-tailed test [α, 0.05; β, 0.2) and estimated a sample size of 78 participants (39 participants per group). Considering potential dropout rate of 20%, a total of 98 participants will be enrolled in this study.

### Patient and Public Involvement
There were no funds or time allocated for patient and public involvement so we were unable to involve patients. We have invited patients to help us develop our dissemination strategy.

**Randomization and blinding**

Patients will be randomized into a control group or experimental group in a 1:1 ratio based on random numbers generated by Excel spreadsheet. Sealed opaque envelopes were used for allocation concealment. A researcher will generate the allocation sequence, and another researcher will assign participants to the control or experimental group. The assessors and statisticians were blinded to randomization and did not participate in the treatment.

**Interventions**

**Control group**

Patients in control group will receive conventional treatment including medication therapy and invasive interventional therapy.

Medication therapy

1. Anticonvulsion medicine

   Gabapentin: Starting dose of 0.3 g on day 1, 0.6 g on day 2, and 0.9 g on day 3; then a maintenance dose of 0.9 g/day, adjusted based on the patient's reaction.

   Pregabalin: Starting dose of 75 mg twice a day; then adjusted based on the patient's reaction.
2. Opioid analgesics

Oxycodone and acetaminophen: 1 tablet 3 times a day, adjusted based on the patient's pain intensity.

3. Neural nutrients

Mecobalamin: 0.5 mg three times a day.

Invasive interventional therapy.

Pulsed radiofrequency regulation guided by low-dose computed tomography will be administered based on the patient's condition.

**Experimental group**

The experimental group will be treated with ESWT in addition to conventional therapy. The patient may be placed in the prone, lateral, or seated position depending on the painful area. Treatment with ESWT will be performed with a radial extracorporeal shockwave generator (MASTERPULS MP100; Storz Medical AG, Tägerwilen, Switzerland), and all treatments will be performed by the same therapist who is formally trained in ESWT. After applying the ultrasonographic coupling agent to the skin of treated area, the patients will receive 5000 to 7000 pulses every session by a R15 probe (radius of 15 mm) at a frequency of 10 Hz, with energy gradually increasing from 1 to 4 bar depending on the patient's reaction. The therapist will move the probe in transverse or longitudinal directions along the nerve. The procedure will be performed every 3 to 5 days, and a total of 3 to 5 sessions constitute a therapeutic course.

**Adherence monitoring**
Patients or their family members will be asked to report the actual drug intake to ensure treatment compliance. In addition, the therapist will gradually increase the energy of shockwave from 1 to 4 bar and adjust the energy according to the patient’s reaction to improve adherence to the intervention.

**Outcome measure**

**General conditions**

The patient’s age, gender, body mass index, previous medical history, duration of PHN, area of nerve pain, medication use, and previous treatments will be obtained at baseline.

**Primary outcome**

The visual analogue scale (VAS) will be used to evaluate pain intensity at baseline and at study weeks 1, 4, and 12. This scale is a 10-cm horizontal line with terminal descriptors of 0 (no pain) and 10 (worst imaginable pain) (14). The participants will mark the line position according to their degree of pain, and the VAS score is determined by measuring the distance from 0 to the marked point.

**Secondary outcome**

Secondary outcomes will be collected at baseline and at study weeks 1, 4, and 12.

1. Quality of life will be accessed by 36-Item Short-Form Health Survey (SF-36) which measures three aspects of health: functional ability, well-being, and overall health (15).
2. Anxiety and depression are common mental disorders in patients with chronic pain (16). The psychological state of patients will be measured by the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS).
3. Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI), which comprises 19 questions and 7 sleep components: perceived sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleep medications, and daytime dysfunction (17).

4. Mechanical withdrawal threshold will be tested using Von-Frey hairs (Aesthesiometer, Somedic, Sweden) according to the methods used by Moharić et al. (18) to indicate the level of peripheral sensitization.

5. Plasma levels of TNF-α and IL-6 will be detected before and after ESWT to explore the biochemical mechanisms of ESWT for the treatment of PHN.

The researchers will provide medical advice to participants who complete follow-up to promote participant retention. Participants who discontinue or deviate from intervention protocols will be recorded in the case report form, and their data, including outcome, adverse event, and the reason of dropping out, will be analyzed for further discussion.

**Safety evaluation**

Adverse effects will be recorded, including petechiae and swelling of the skin, allergy, fever, paresthesia, pain aggravation, tissue edema, and any other reported adverse reactions to ESWT. In addition, incidence of adverse effects will be analyzed as a measurement of safety. Serious adverse events are described as events that prolong hospitalization time, cause disability, affect ability to work, or endanger life in clinical trials. If a serious adverse event occurs, treatment will be suspended immediately and remedy actions taken appropriately and freely in time. All serious adverse events will be reported to the Ethics Committee and relevant responsible research units to determine whether to stop the clinical trial.

**Monitoring**
An Independent Data Monitoring Committee (IDMC), which is separate from the trial sponsor and competing interests, will supervise the trial including assessment of the progress, safety data, and efficacy endpoints. The trial sponsor may decide whether to continue, modify, or stop the trial according to the recommendations of the IDMC. The Project Management Group will review the trial conduct monthly. The Trial Steering Group and the IDMC will review trial conduct every 3 months, and the Ethics Committee will review trial conduct annually.

**Data management and statistical analysis**

All original data will be stored in a case report form and any personal information will be protected. The study supervisor will have access to the trial dataset and make the final decision to terminate the trial. Audits of the trial will be performed bimonthly. Data analysis will be performed by SPSS software (version 22; SPSS Inc., Chicago, IL, USA). Continuous data will be presented as mean ± standard deviation, and categorical variables will be reported as numbers or percentages. The basic characteristics of participants will be described and compared by the student $t$ test to ensure comparability. All statistical analysis followed the principle of intent-to-treat analysis. The difference in treatment effect between the two groups will be evaluated by one-way analysis of variance (ANOVA) with a repeated measures ANOVA to analyze the changes over time in the intervention group. The duration of PHN and painful segment, as potential factors, will be assessed using the logistic regression. All tests will be single-sided, and $p \leq 0.05$ will be considered statistically significant. All statistical analysis will follow the principle of intent-to-treat analysis. The patients randomized to the intervention group but who do not adhere to the intervention will be included in the final data analysis. Imputation method will be used to handle missing data if the assumption of missing at random is met.

**Discussion**

As a common condition in older adults who have had shingles, PHN seriously affects quality of life and mental health. Although multiple therapies for PHN are available, a recommended effective and safe
treatment is still lacking. The aim of this randomized controlled trial is to assess the efficacy and safety of ESWT in patients with PHN and explore the potential biochemical mechanisms of this treatment.

Persistent inflammation, oxidative stress-mediated injury, and cytokines activation are shown to play an important role in the pathological mechanism of neuropathic pain (7). Some studies suggest that TNF-α, IL-1, IL-6, IL-17 may be the main pro-inflammatory cytokines in neuropathic pain (19). To the knowledge of the researchers for this proposed trial, the mechanism of ESWT for PHN may be related to immune regulation and analgesic effect. A recent study showed that ESWT may reduce the plasma levels of TNF-α and IL-6, which had an anti-inflammatory effect (20). In addition, decreased substance P levels after ESWT may produce analgesic effects (21). Hopefully, the results of the proposed study will confirm the effect of ESWT for patients with PHN and provide clinical evidence to support its use. Finally, if the study hypothesis is verified, ESWT may be considered for recommendation as an effective and safe therapy for PHN.

The proposed study has several limitations. First, it is a single-center clinical trial, which might influence participant recruitment. Second, this clinical trial is single-blind because a double-blind design would be difficult to ensure considering the therapeutic properties of ESWT, which might cause patient bias. In addition, the primary outcome measure is a subjective evaluation, which may be a potential risk for bias because participants will know in which arm of the trial they are enrolled. Another limitation is that, although the trial follow-up is 3 months after the treatment, extended follow-up may be needed to demonstrate the benefits of ESWT in further studies.

List Of Abbreviations

ANOVA Analysis of variance
ESWT Extracorporeal shockwave therapy
IDMC Independent Data Monitoring Committee
PSQI Pittsburgh Sleep Quality Index
SAS Self-Rating Anxiety Scale
SDS Self-Rating Depression Scale
VAS Visual analogue scale

Trial Status

The protocol version is 2.0 (issue date: 29 October 2019). Recruitment began in February 2020 and will probably be completed at the end of May 2020.
Declarations

Ethics approval and consent to participate

The study was approved by the ethics committee of West China Hospital of Sichuan University (Version 2.0 of this protocol was approved on 30th December 2019, reference 2019[814]) and has been prospectively registered at Chictr.org.cn (ChiCTR1900025828). Informed consent will be written from all participants and are available from the corresponding author on request.

Protocol amendments

If there are any changes to the protocol, the sponsor and funder will be notified firstly, then the centers will be notified. A copy of the revised protocol will be sent to the PI to add to the Investigator Site File. Any deviations from the Protocol will be fully documented using a breach report form. The researchers will update the protocol in the clinical trial registry.

Consent for publication

Not applicable.

Results dissemination

The results of this study will be submitted for publication in peer-reviewed journals and/or presented at conferences.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interest

The authors declare that they have no conflicts of Interest.

Funding

This study is supported by grant 2019HXFH069 from 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University and the grant 2018JY0105 from Science &Technology Department of Sichuan Province and 18ZA0158 from Education Department of Sichuan. These projects will not participate in any aspect of the trial, including design, data collection, analysis or interpretation.

Author contributions
LC, RHZ designed this randomized controlled trial and wrote the protocol. YL is the leader and supervisor of the project who is responsible for all aspects of local organisation including identifying potential recruits and taking consent. PLY and LY contributed equally to the design of the study, with emphasis on the statistical analysis and sample size analyses, critical revision of the manuscript and final approval of the study. LC will perform ESWT in treatments. FGS and YW will collect the data. ZRH will perform the statistical analysis. All authors have read and approved the final manuscript.

Acknowledgements

The authors would like to thank Enago (www.enago.cn) for the English language review.

References


Figures
Figure 1

CONSORT Flow Diagram. ESWT, extracorporeal shockwave therapy; VAS, visual analogue scale; SF-36, 36-item short-form health survey; SAS, self-rating anxiety Scale; SDS, self-rating depression scale; PSQI, Pittsburgh sleep quality index.
<table>
<thead>
<tr>
<th>TIMEPOINT**</th>
<th>Enrolment</th>
<th>Allocation</th>
<th>Intervention</th>
<th>Post-intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Admission</td>
<td>Allocation</td>
<td>Hospitalization</td>
<td>1 week</td>
</tr>
<tr>
<td>ENROLMENT:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic characteristics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTERVENTIONS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESWT+ conventional treatment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>conventional treatment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASSESSMENTS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAS</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SF-36</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SAS</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SDS</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PSQI Mechanical withdrawal threshold</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>plasma levels of TNF-α. IL-6</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

**Figure 2**

Recommendation for Interventional Trials (SPIRIT) schedule of enrollment, interventions and assessments. ESWT, extracorporeal shockwave therapy; VAS, visual analogue scale; SF-36, 36-item short-form health survey; SAS, self-rating anxiety Scale; SDS, self-rating depression scale; PSQI, Pittsburgh sleep quality index.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SPIRITchecklist.docx